|Awarded On||November 19, 2014|
|Title||Druggable Targets that Regulate the Antitumor Activity of ER-beta|
|Award Mechanism||Bridging the Gap: Early Translational Research Awards|
|Institution/Organization||The University of Texas Health Science Center at San Antonio|
|Principal Investigator/Program Director||Rong Li|
Estrogen Receptor beta (ER-beta) is often viewed as the “Cinderella sister” of ER-alpha with just the “opposite personality”. Unlike ER-alpha that has the known tumor-promoting activity, ER-beta has an antitumor activity in breast cancer. Because ER-beta is present in as many as half of all breast cancer cases, rallying its tumor-inhibitory activity is an attractive therapeutic strategy. However, this therapeutic potential of ER-beta has been largely untapped.
The current proposal, which is aimed at mobilizing the antitumor activity of ER-beta, is based on two recent exciting developments in ER-beta research. First, a highly potent ER-beta-specific activator was shown recently to be clinica...